Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV plasmid DNA vaccine
- Development stage
- Unknown
- Lead developer
- Swedish Institute for Infectious Disease Control
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
HIVIS-DNA is an investigational, multigene, multiclade plasmid DNA vaccine candidate developed by the Swedish Institute for Infectious Disease Control (SMI) in collaboration with the Karolinska Institutet and Karolinska University Hospital, and manufactured by Vecura. The vaccine is composed of seven plasmids encoding multiple HIV-1 antigens, specifically gp160 (Env) subtypes A, B, and C; Rev subtype B; Gag subtypes A and B; and a mutated reverse transcriptase (RTmut) subtype B. HIVIS-DNA is designed to prime the immune system to elicit both cellular (CD4+ and CD8+ T-cell) and humoral (antibody) immune responses against HIV-1. In clinical trials (such as HIVIS01/02, HIVIS03, and HVRRICANE), it has been evaluated primarily in heterologous prime-boost regimens, where HIVIS-DNA priming is followed by boosting with a recombinant modified vaccinia Ankara (MVA-CMDR) vaccine.
- Other names
- HIVIS-DNA vaccineHIVIS DNA vaccineHIV-1 DNA vaccine (HIVIS DNA)
02
Targets
Gag (HIV-1 Gag polyprotein)Rev (HIV-1 Rev)Env (HIV-1 envelope glycoprotein)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on HIV plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV plasmid DNA vaccine.